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Research and development costs associated with successful market release of anticancer 
therapeutics are notoriously high. Whilst traditional drug screening approaches have served the 
cancer research community well over the last few decades [1], drug discovery programs are 
protracted, driving a continuous demand to develop non-traditional preclinical tools that are 
accurate, high throughput and cost-effective. 
Fourier Transform Infrared micro-spectroscopy (FTIRM) can provide an operational platform for such 
a strategic approach. The method involves a non-destructive and label-free process of analysis that 
enables subsequent histological reporting. The technique provides a unique fingerprint spectrum 
containing global biochemical information of the main macromolecules that compose a cell; either 
at the single cell level, or as an overall signal from a global cell population.  
Evidence of drug-cell interaction and drug efficacy can be inferred by the acquisition of infrared 
spectral data from drug-treated cells (Figure 1). It is possible to detect discriminatory changes to the 
cellular IR signal even before visible morphological changes are evident, producing data of diagnostic 
significance for drug screening applications. Interestingly, an IR cell apoptosis-specific marker was 
identified and corroborated with flow cytometry over a decade ago [2]. Progress of the method for 
preclinical application, however, has been hampered; physical spectral distortion phenomena and 
data processing hurdles have resulted in concerns about data misinterpretation. Recently, however, 
many of these issues have now been addressed by advances in the theoretical understanding 
underpinning the spectral acquisition process [3]. Coupled with the internationally-strong bio-
spectroscopy community driving to establish robust and standardized methodologies in order to 
improve inter lab repeatability, FT-IRMS is beginning to show its true potential [4].  
As a result, cellular responses to therapeutic agents can now be studied with FTIRM in confidence. 
The technique has high potential as a preclinical tool in the early drug discovery process in terms of 
identifying lead compounds and weeding out weak candidates. In addition to determining apoptotic 
signals, knowledge of the IR spectral changes associated with inherent cell cycle chemistry has also 
improved. This will undoubtedly enhance information gained when distinguishing spectral signals of 
normal cellular events with cellular responses to cycle-arresting drugs. Detection and classification of 
growth phases of individual cells based on their label-free IR spectra has been demonstrated to be 
?????????????????????
??????????????????????? ???????????????????????????????????????? ????????
achievable on both a chemically-fixed [5] and live-cell timescale [6] thus, highlighting its diverseness. 
Furthermore, as demonstrated in FTIRM studies of multiple cell lines, it is possible to achieve general 
classification of drug mode of action by the cellular response [7]. As a preclinical tool, this provides 
significant benefit for the analysis of experimental compounds with unknown chemical mechanisms.   
In addition to pre-clinical screening, there are clinical applications for using an IR based tool that will 
result in beneficial patient impact. For instance, evidence gathered thus far has indicated that IR-
based detection of a cellular response to sub-toxic doses is possible [8] and efforts are also being 
directed to the study of IR spectral biomarkers for cellular sensitivity and resistance [9]. Close 
monitoring of IR spectral changes in such markers, used in combination with other analytical 
methods, could provide fundamental indications of favourable patient responders to certain drugs 
for exploitation in personalised medicine.  
The majority of insights gained from drug-cell interaction studies on the cellular level in previous 
years have been discovered using synchrotron-FTIRM due to their brilliant sources. This is because 
the IR light had to be confined to small sample areas in order to probe a single biological cell. With 
such constraints imposed on the light signal, conventional benchtop IR systems with a low-
throughput thermal source struggled to achieve an effective signal to noise ratio (SNR). Conversely, 
the use of a high-intensity synchrotron light source ensured that the SNR was uncompromised.  
The use of synchrotron radiation may be advantageous for specialised, focused experiments, 
however their use for the application of IR preclinical screening tool it is an impractical notion. 
Fortuitously, the field has benefited from a recent surge in technological advance. Benchtop IR 
systems with the standard thermal sources can now achieve comparable SNR at the single cell level 
due to the advent of 128 × 128 element focal plane array detectors [10]; an infrared spectrum can 
be recorded on a pixel by pixel basis, sampling a large area of multiple cells in a spatially-resolved 
chemical map. The SNR can be increased by the identification and sub sequential averaging of 
multiple spectra that are associated with an individual single cell. Jimenez-Hernandez et al [5] 
demonstrated this approach and was able to sample multiple cells 10- ? ?ʅŵŝŶĚŝĂŵĞƚĞƌǁŝƚŚŝŶĂ
 ? ? ?п ? ? ?ʅŵĂƌĞĂƐŝŵƵůƚĂŶĞŽƵƐůǇ ?Until very recently, such benchtop FTIR imaging studies have 
been ƉĞƌĨŽƌŵĞĚĂƚƉŝǆĞůƌĞƐŽůƵƚŝŽŶŽĨ ? ? ?ʅŵ - far behind the diffraction-limited pixel resolution of 
 ? ? ?ʅŵ achieved at the unique infrared beamline of the Synchrotron Radiation Center, Wisconsin). 
Now, however, it is possible to configure a benchtop system for enhanced magnification,  reducing 
pixel resolution from 5.5 ʅŵƚŽ ? ? ?ʅŵƵƐŝŶŐƚŚĞƐĂŵƉůĞŽďũĞĐƚŝǀĞ, allowing for sub-cellular imaging 
possibilities [11].  
In addition, there are now even more incentives to drive IR as a diagnostic tool due to the 
introduction of discrete frequency infrared (DFIR) imaging. The conventional thermal source is 
replaced with a high-intensity tuneable laser that has a customisable frequency range. This new IR 
technique provides the opportunity to collecting a handful of salient frequencies or discrete data 
ranges of discriminatory interest, thus creating a significant reduction in spectral acquisition time, 
with no SNR penalty [12]. By the combination of a multi-culture cell assay and DFIR technology, a 
preclinical high-throughput IR tool for objective classification of potent novel anticancer agents can 
now be realised.  
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Figure 1: Infrared micro-spectroscopy can probe the global biochemical cellular fingerprint in a stain-
free and non-destructive process, revealing spectral biomarkers of cytotoxic efficacy in drug-cell 
interaction assays. Recent developments in technology have afforded the power to quickly provide 
this information, thus highlighting the technique as a potential preclinical tool in the discovery 
process of potent novel chemotherapeutics. 
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